InMode Competitors

InMode (NASDAQ:INMD) and LivaNova (NASDAQ:LIVN) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Profitability

This table compares InMode and LivaNova's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings for InMode and LivaNova, as reported by MarketBeat.

InMode currently has a consensus price target of $71.50, suggesting a potential downside of 18.11%. LivaNova has a consensus price target of $69.3333, suggesting a potential downside of 14.76%. Given LivaNova's higher probable upside, analysts plainly believe LivaNova is more favorable than InMode.

Valuation and Earnings

This table compares InMode and LivaNova's top-line revenue, earnings per share (EPS) and valuation.

InMode has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

35.7% of InMode shares are owned by institutional investors. Comparatively, 89.1% of LivaNova shares are owned by institutional investors. 0.5% of LivaNova shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

InMode has a beta of 1.95, suggesting that its share price is 95% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.

Summary

InMode beats LivaNova on 9 of the 14 factors compared between the two stocks.

CONMED (NYSE:CNMD) and InMode (NASDAQ:INMD) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares CONMED and InMode's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and target prices for CONMED and InMode, as reported by MarketBeat.com.

CONMED presently has a consensus target price of $103.25, suggesting a potential downside of 20.71%. InMode has a consensus target price of $71.50, suggesting a potential downside of 18.11%. Given InMode's stronger consensus rating and higher possible upside, analysts plainly believe InMode is more favorable than CONMED.

Valuation & Earnings

This table compares CONMED and InMode's gross revenue, earnings per share and valuation.

InMode has lower revenue, but higher earnings than CONMED. CONMED is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

35.7% of InMode shares are owned by institutional investors. 5.4% of CONMED shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

CONMED has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, InMode has a beta of 1.95, indicating that its share price is 95% more volatile than the S&P 500.

Summary

InMode beats CONMED on 11 of the 14 factors compared between the two stocks.

Outset Medical (NASDAQ:OM) and InMode (NASDAQ:INMD) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Outset Medical and InMode's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Outset Medical and InMode, as reported by MarketBeat.com.

Outset Medical presently has a consensus target price of $56.50, suggesting a potential upside of 4.82%. InMode has a consensus target price of $71.50, suggesting a potential downside of 18.11%. Given Outset Medical's higher possible upside, research analysts plainly believe Outset Medical is more favorable than InMode.

Valuation & Earnings

This table compares Outset Medical and InMode's gross revenue, earnings per share and valuation.

InMode has higher revenue and earnings than Outset Medical.

Institutional & Insider Ownership

84.6% of Outset Medical shares are owned by institutional investors. Comparatively, 35.7% of InMode shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

InMode beats Outset Medical on 5 of the 7 factors compared between the two stocks.

BioLife Solutions (NASDAQ:BLFS) and InMode (NASDAQ:INMD) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Institutional and Insider Ownership

67.7% of BioLife Solutions shares are owned by institutional investors. Comparatively, 35.7% of InMode shares are owned by institutional investors. 22.3% of BioLife Solutions shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares BioLife Solutions and InMode's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and price targets for BioLife Solutions and InMode, as reported by MarketBeat.

BioLife Solutions presently has a consensus target price of $46.6667, suggesting a potential upside of 36.57%. InMode has a consensus target price of $71.50, suggesting a potential downside of 18.11%. Given BioLife Solutions' higher possible upside, analysts clearly believe BioLife Solutions is more favorable than InMode.

Valuation and Earnings

This table compares BioLife Solutions and InMode's gross revenue, earnings per share and valuation.

InMode has higher revenue and earnings than BioLife Solutions. InMode is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

BioLife Solutions has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, InMode has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500.

Summary

InMode beats BioLife Solutions on 9 of the 14 factors compared between the two stocks.

Natus Medical (NASDAQ:NTUS) and InMode (NASDAQ:INMD) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Institutional and Insider Ownership

89.7% of Natus Medical shares are owned by institutional investors. Comparatively, 35.7% of InMode shares are owned by institutional investors. 1.5% of Natus Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Natus Medical and InMode's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and price targets for Natus Medical and InMode, as reported by MarketBeat.

InMode has a consensus target price of $71.50, suggesting a potential downside of 18.11%. Given InMode's stronger consensus rating and higher possible upside, analysts clearly believe InMode is more favorable than Natus Medical.

Valuation and Earnings

This table compares Natus Medical and InMode's gross revenue, earnings per share and valuation.

InMode has lower revenue, but higher earnings than Natus Medical. Natus Medical is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Natus Medical has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Comparatively, InMode has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500.

Summary

InMode beats Natus Medical on 11 of the 14 factors compared between the two stocks.

AxoGen (NASDAQ:AXGN) and InMode (NASDAQ:INMD) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Analyst Ratings

This is a summary of recent ratings and price targets for AxoGen and InMode, as reported by MarketBeat.

AxoGen presently has a consensus target price of $23.75, suggesting a potential upside of 25.99%. InMode has a consensus target price of $71.50, suggesting a potential downside of 18.11%. Given AxoGen's higher possible upside, analysts clearly believe AxoGen is more favorable than InMode.

Institutional and Insider Ownership

78.4% of AxoGen shares are owned by institutional investors. Comparatively, 35.7% of InMode shares are owned by institutional investors. 6.9% of AxoGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

AxoGen has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, InMode has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500.

Valuation and Earnings

This table compares AxoGen and InMode's gross revenue, earnings per share and valuation.

InMode has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AxoGen and InMode's net margins, return on equity and return on assets.

Summary

InMode beats AxoGen on 11 of the 14 factors compared between the two stocks.